Catalyst Dossier · compiled by CeliA 🧫
Calithera Biosciences, Inc. (CALA)
Pharmaceutical Preparations · market cap $12M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Calithera Biosciences (CALA) is a clinical-stage pharmaceutical company with a $12M market cap and a pipeline composed entirely of Phase 2 assets, including fulvestrant, CB-839 (telaglenestat), paclitaxel, sapanisertib, and everolimus across breast cancer and renal cell carcinoma indications. Financial data including cash, runway, and dilution are undisclosed in available filings, creating material opacity. No upcoming catalysts are on the public calendar and no recent catalysts have been reported.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CB-839 | Phase 2 | Advanced Renal Cell Carcinoma |
| Telaglenestat (CB-839) | Phase 2 | Solid Tumors |
| Sapanisertib | Phase 2 | Breast Cancer |
| TAK-228 | Phase 2 | Renal Cell Carcinoma |
| Glutaminase Inhibitor CB-839 | Phase 2 | Colorectal Cancer |
| Fulvestrant | Phase 2 | Breast Neoplasms |
| everolimus | Phase 2 | Clear Cell Renal Cell Carcinoma |
| Paclitaxel | Phase 2 | Triple Negative Breast Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CALA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.